ORTEXORTEX News
Tracking PRU? Get live short interest, options flow, and signals on ORTEX.Sign up free →
PR
Trader NotePRU

PRU Short Interest Eases Before Earnings as Analysts Trim Targets

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 2 min readdata as of 28 Oct 2026, 18:46

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

Prudential Financial enters its November 3 earnings date with short sellers pulling back modestly from last week's year-long high, while a broad wave of analyst target cuts has pushed the consensus price well below where the stock trades today.

Short interest has retreated from the peak flagged in the previous note. Borrowed shares fell roughly 5% over the past week to 14.3 million, bringing the position to 4.1% of free float, down from the 4.3% high reached last week. The monthly picture remains elevated: the position is still around 6% above where it was 30 days ago, and the jump from approximately 13.4 million to nearly 15 million shares that happened in a single session on September 23 has not been unwound. The borrow market remains completely open to new shorts. Availability has actually tightened this week, moving from around 1,800% to 1,608%, but that still means roughly 16 shares are available to borrow for every one already lent out, and the cost to borrow is just 0.41%, near the bottom of its 30-day range. There is no friction keeping shorts out.

Options positioning adds little signal either way. The put/call ratio of 1.05 sits fractionally below its 20-day average of 1.06, a z-score of minus 0.24 that puts it squarely in neutral territory. The 52-week high on the PCR is 1.46, so current levels represent no particular alarm. Taken together, the positioning picture reads as range-bound caution rather than any acute bet in either direction.

The analyst story is the more striking development. Every single change logged over the past two weeks has been a target cut, with no upgrades and no new initiations. Morgan Stanley trimmed its target to $100 while maintaining Underweight. Wells Fargo cut to $103, also Underweight. JP Morgan lowered to $124, maintaining Neutral. The consensus price target now stands at $107.60, roughly 7% below the current price of $115.21. That gap matters: the stock is trading above what the collective analyst view says it is worth, even before accounting for the several bearish ratings in the mix. The earnings yield factor scores at the 73rd percentile, suggesting the valuation is not obviously stretched on that measure, but EPS momentum ranks in the fifth percentile on a 30-day basis and the 11th on 90 days, reflecting the deteriorating estimate trend that is driving those cuts.

Retail attention has picked up ahead of the print. Wikipedia page views are running more than two standard deviations above their 90-day average, the highest reading in the ORTEX alt data series. That is an attention signal, not a revenue indicator, but it confirms that the November 3 release is drawing more eyes than usual.

Among peers, PFG gained 3.7% over the week and AFL added 1.4%, while MET and RGA both slipped, with RGA down 1.7%. PRU's flat week roughly tracks the median of its closest comparables, with no meaningful divergence to explain.

What to watch on November 3 is whether PRU prints above or below the level implied by an analyst consensus that has moved decisively lower in the weeks before the release, and whether the partial unwind of the short position continues or reverses in the days that follow.

Stocks in this article

See the live data behind this article on ORTEX.

Open PRU on ORTEX →

How this article was generated

Generated
28 Oct 2026, 18:48
Data as of
28 Oct 2026, 18:46
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt DataPrevious Mi Articles

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.